Alinity m Resp-4-Plex molecular assay gets EUA

March 11, 2021—The FDA granted emergency use authorization for Abbott's Alinity m Resp-4-Plex molecular assay, which detects and differentiates SARS-CoV-2, influenza A and B, and respiratory syncytial virus in one test.

The Alinity m Resp-4-Plex test can be conducted with an anterior nasal or nasopharyngeal swab collected by a health care provider or an anterior nasal swab specimen self-collected at a health care location from people suspected by their provider of respiratory viral infection consistent with COVID-19. The CE-marked test will run on Abbott's Alinity m system, which uses PCR technology and can run up to 1,080 tests in 24 hours.

Abbott also announced that the EUA for the company's Alinity m SARS-CoV-2 test has been updated to include an asymptomatic claim and a pooling claim, which allows up to five samples to be tested at the same time.